New study tests best way to deliver antibiotic combo against superbugs

NCT ID NCT07478484

Recruiting now Disease control Sponsor: Jing Zhou Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing two different ways of giving a combination of two antibiotics (ceftazidime-avibactam and aztreonam) to treat serious infections caused by bacteria that are resistant to many drugs. The researchers want to see if giving the drugs one after the other works as well as giving them together. The study will include 144 people with infections like pneumonia, urinary tract infections, or bloodstream infections. The goal is to find the safest and most effective way to deliver this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ceftazidime-avibactam combined with aztreonam
What this could lead to: If successful, this study could identify the best way to give these two antibiotics together, improving treatment for serious infections that resist many other drugs.
What could go wrong: This is a Phase 4 trial comparing infusion methods, not testing a new drug. The results may not show a clear advantage, and the infections involved are very difficult to treat, so outcomes may still be poor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AZTREONAM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gram-negative bacterial infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AZTREONAM CARBAPENEM-RESISTANT CEFTAZIDIME-AVIBACTAM GRAM-NEGATIVE BACTERIAL INFECTION METALLO-Β-LACTAMASE-PRODUCING

Contacts and locations

Show contact details

Locations

Jing Zhou
RECRUITING

Nanjin, Jiangsu, 210000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.